SNOA - Sonoma Pharmaceuticals, Inc. Total Debt to Capital

Sonoma Pharmaceuticals (SNOA) has reached a maturity stage by scaling the distribution of its dermatological products through veterinary channels and pharmacies. This price action, visualized with the 0.12 indicator, complements the stability analysis of a business that leverages unique Microcyn patents to retain patients and sustain profits. The company generates revenue through the production of specialized hypochlorous acid solutions for the therapy of mucous membranes and skin.

Due to the outsourcing of skincare product manufacturing, scaling Sonoma Pharmaceuticals (SNOA) across pharmacy chains remains cost-effective, making the ratio of financial liabilities to equity a key indicator of leverage efficiency. This metric compares total borrowings with net assets, allowing investors to determine whether expansion is funded by equity or through a risky increase in debt load.